delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular
Company profile
Ticker
DCTH
Exchange
Website
CEO
Jennifer Simpson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DELCATH SYSTEMS INC
SEC CIK
Corporate docs
Subsidiaries
1.Delcath Systems Limited • 2.Delcath UK Systems Limited • 3.Delcath Systems GmbH • 4.Delcath Systems B.V. ...
IRS number
61245881
DCTH stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
10 May 24
424B3
Prospectus supplement
9 May 24
S-3/A
Shelf registration (amended)
8 May 24
S-3
Shelf registration
29 Apr 24
8-K
Entry into a Material Definitive Agreement
26 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
D
$7.00 mm in equity / options, sold $7.00 mm, 17 investors
26 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
Transcripts
DCTH
Earnings call transcript
2023 Q4
26 Mar 24
DCTH
Earnings call transcript
2023 Q3
13 Nov 23
DCTH
Earnings call transcript
2023 Q1
12 May 23
DCTH
Earnings call transcript
2022 Q4
27 Mar 23
DCTH
Earnings call transcript
2022 Q3
8 Nov 22
DCTH
Earnings call transcript
2022 Q2
8 Aug 22
DCTH
Earnings call transcript
2022 Q1
10 May 22
DCTH
Earnings call transcript
2021 Q4
25 Mar 22
DCTH
Earnings call transcript
2021 Q3
9 Nov 21
DCTH
Earnings call transcript
2021 Q2
10 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 40.50 mm | 40.50 mm | 40.50 mm | 40.50 mm | 40.50 mm | 40.50 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.52 mm | 2.89 mm | 3.05 mm | 2.54 mm |
Cash used (since last report) | n/a | n/a | 25.93 mm | 21.33 mm | 22.51 mm | 18.69 mm |
Cash remaining | n/a | n/a | 14.57 mm | 19.17 mm | 17.99 mm | 21.81 mm |
Runway (months of cash) | n/a | n/a | 4.1 | 6.6 | 5.9 | 8.6 |
Institutional ownership, Q4 2023
35.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 2 |
Closed positions | 36 |
Increased positions | 3 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 135.37 mm |
Total shares | 9.90 mm |
Total puts | 0.00 |
Total calls | 1.60 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vivo Opportunity Fund | 4.88 mm | $35.39 mm |
Biotechnology Value Fund L P | 1.56 mm | $11.32 mm |
Hirschman Orin | 1.54 mm | $6.25 mm |
Rosalind Advisors | 1.10 mm | $2.69 mm |
Soleus Capital Master Fund | 806.42 k | $4.57 mm |
WealthPlan Investment Management | 17.44 k | $72.56 mm |
Quent Capital | 519.00 | $2.16 mm |
Cutler | 400.00 | $1.00 k |
Allworth Financial | 100.00 | $416.00 k |
Umb Bank N A | 2.00 | $8.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Mar 24 | Vojo Vukovic | Common Stock | Grant | Acquire A | No | No | 3.72 | 26,882 | 100.00 k | 126,882 |
19 Mar 24 | Michel Gerard J | Common Stock | Grant | Acquire A | No | No | 3.72 | 40,323 | 150.00 k | 302,668 |
19 Mar 24 | Sandra Pennell | Common Stock | Grant | Acquire A | No | No | 3.72 | 26,881 | 100.00 k | 61,052 |
19 Mar 24 | Kevin Muir | Common Stock | Grant | Acquire A | No | No | 3.72 | 13,441 | 50.00 k | 18,582 |
19 Mar 24 | David L. Hoffman | Common Stock | Grant | Acquire A | No | No | 3.72 | 20,161 | 75.00 k | 74,330 |
News
Delcath Systems Announces Publication Of Results From Pivotal FOCUS Study In Metastatic Uveal Melanoma Patients Treated With HEPZATO KIT
6 May 24
Netflix To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
27 Mar 24
HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $20
27 Mar 24
Delcath Systems Q4 GAAP EPS $(0.48) Beats $(0.51) Estimate, Sales $539.00K Miss $540.00K Estimate
26 Mar 24
Earnings Scheduled For March 26, 2024
26 Mar 24
Press releases
Delcath Systems to Host First Quarter 2024 Earnings Call
7 May 24
Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
6 May 24
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 May 24
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
26 Mar 24